tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Cell-in-a-Box'

Nuvilex’s Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials

Nuvilex’s Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials

Written by ι Stock Market Media Group Staff — February 19, 2014

Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and pharmaceutical companies like Eli Lilly and Celgene. If the company’s pancreatic cancer treatment that combines the proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™ with the anti-cancer drug ifosfamide can produce the same or better data in its upcoming late-phase clinical trials in advanced, inoperable pancreatic cancer than ...

Read More →
0

Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment without Gemcitabine

Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment without Gemcitabine

Written by ι Stock Market Media Group Staff — December 16, 2013

Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered – the company’s late stage clinical trials in advanced, inoperable pancreatic cancer that is.  In an editorial that accompanied the findings of an epidemiological study of patients with pancreatic cancer published in the November 20 issue of the Journal of the National Cancer Institute (JNCI), treatments using the drug gemcitabine ...

Read More →
0

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Nuvilex, Inc. and Celgene Corp. Can Both Replace Eli Lilly’s Cancer Drug Gemzar

Written by ι Stock Market Media Group Staff — May 20, 2013

The race is on, and patients with advanced stage, inoperable pancreatic cancer will be the recipients of the winner’s treatment.  Two biotechnology companies are registering impressive data in each of their own pancreatic cancer trials, so impressive in fact, Eli Lilly & Co. (NYSE: LLY) is surely feeling its long time reign as the current standard single-drug treatment for the disease being threatened.  Nuvilex, Inc. (OTCQB: NVLX) and Celgene Corp. (NASDAQ: ...

Read More →
0

Nuvilex, Inc. Cell Encapsulation Could Mimic Combination Chemotherapy

Nuvilex, Inc. Cell Encapsulation Could Mimic Combination Chemotherapy

Written by ι Stock Market Media Group Staff — May 15, 2013

Nuvilex, Inc. (OTCQB: NVLX) has had its living cell encapsulation or “Cell-in-a-Box” technology tested again and again, and each time it has proven it can do exactly what it’s intended to do.  To date, the proprietary technology has more than impressed and continuously returns remarkable data after each study.  In a study not yet discussed, “Cell-in-a-Box” was used to enclose cells that activate more than one anticancer drug simultaneously.  This is ...

Read More →
0

Nuvilex, Inc. COO Discusses Upcoming Phase III Pancreatic Cancer Trials

Nuvilex, Inc. COO Discusses Upcoming Phase III Pancreatic Cancer Trials

Dr. Gerald Crabtree Addresses Study Sites, Seeking Fast Track & Orphan Drug Status and More

Written by ι Stock Market Media Group Staff — May 13, 2013

Nuvilex, Inc. (OTCQB: NVLX) COO Dr. Gerald Crabtree is no stranger to late stage clinical trials or dealing with blockbuster therapies for cancer patients.  It’s likely that is exactly why he’s the COO at the small Silver Spring, Maryland, biotech.  The road that Nuvilex is currently on – preparing for a large scale Phase III clinical trial ...

Read More →
0

Nuvilex, Inc. Shows Success Treating Mammary Tumors Using Cell Encapsulation Technology

Nuvilex, Inc. Shows Success Treating Mammary Tumors Using Cell Encapsulation Technology

Written by ι Stock Market Media Group Staff — May 7, 2013

Nuvilex, Inc. (OTCQB: NVLX) should be convincing investors by now that its technology could truly change the face of healthcare.  Many know of the company’s “Cell-in-a-Box” technology for its performance in clinical trials for advanced, inoperable pancreatic cancer, and its performance in pre-clinical studies for diabetes where it essentially created a type of “artificial pancreas.”  But, the company isn’t stopping there when it comes to showing the technology’s flexibility.

“Cell-in-a-Box” or living ...

Read More →
0
Page 7 of 9 «...56789
ContactUs.com